IKS014 in Advanced Solid Tumors That Express HER2
Conditions
Breast Cancer · Gastric Cancer · Gastroesophageal-junction Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
Contact: Principal Investigator (Monica Mita, MD)Dana Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Principal Investigator (Nancy Lin, MD)Tennessee Oncology, Nashville, Tennessee, United States
Contact: Principal Investigator (Jeffrey Russell, MD)START Dallas - Fort Worth, Fort Worth, Texas, United States
Contact: Principal Investigator (Henry Xiong, MD)Concord Repatriation General Hospital Medical Oncology Clinical Trials Unit, Concord, New South Wales, Australia
Contact: Principal Investigator (Tam Bui, MD)Macquarie University, Sydney, New South Wales, Australia
Contact: Principal Investigator (Dhanusha Sabanathan, MD)Westmead Hospital, Westmead, New South Wales, Australia
Contact: Principal Investigator (Adnan Nagrial, MD)Peninsula & South Eastern Haematology and Oncology Group (PSEHOG), Frankston, Victoria, Australia
Contact: Principal Investigator (Vinod Ganju, MD)Alfred Health, Melbourne, Victoria, Australia
Contact: Principal Investigator (Malaka Ameratunga, MD)Linear Clinical Research, Nedlands, Western Australia, Australia
Contact: Principal Investigator (Peter Lau, MD)Auckland City Hospital, Auckland, New Zealand
Contact: Principal Investigator (Jane So, MBChB)National Cancer Centre Singapore, Singapore, Singapore
Contact: Principal Investigator (Jing Ying Tira Tan, MBBS)Tan Tock Seng Hospital, Singapore, Singapore
Contact: Principal Investigator (Yue Ming Valerie Heong, MBBS)
Study leads
James O'Leary, MD
Study Director
Iksuda Therapeutics